Drug Treatment for Obesity in the Post-Sibutramine Era

ISSN： 0114-5916

Source： Drug Safety, Vol.34, Iss.8, 2011-08, pp. : 641-650

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The discovery and status of sibutramine as an anti-obesity drug

By Luque C.A. Rey J.A.

European Journal of Pharmacology, Vol. 440, Iss. 2, 2002-04 ,pp. : 119-128

Elsevier

Access to resources Recommend Favorite

Currently Available Drugs for the Treatment of Obesity: Sibutramine and Orlistat

Mini Reviews in Medicinal Chemistry, Vol. 7, Iss. 1, 2007-01 ,pp. : 3-10

Bentham Science Publishers

Access to resources Recommend Favorite

Safety Assessment of an Anti-Obesity Drug (Sibutramine): A Retrospective Cohort Study

By Tyczynski Jerzy E.

Drug Safety, Vol. 35, Iss. 8, 2012-08 ,pp. : 629-644

Adis International

Access to resources Recommend Favorite

Sibutramine: current status as an anti-obesity drug and its future perspectives

By Sharma Bikash Henderson David C

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 12, 2008-08 ,pp. : 2161-2173

Informa Healthcare

Access to resources Recommend Favorite

Giardiasis in the Post Genomic Era: Treatment, Drug Resistance and Novel Therapeutic Perspectives

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 10, Iss. 4, 2010-08 ,pp. : 283-294

Bentham Science Publishers

Access to resources Recommend Favorite